signaling β miR-21 mediates hematopoietic suppression in MDS by activating TGF-

[1]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[2]  C. Croce,et al.  Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes , 2011, British journal of haematology.

[3]  M. Bitzer,et al.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. , 2011, Cancer research.

[4]  Kevin Struhl,et al.  STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. , 2010, Molecular cell.

[5]  N. Kaminski,et al.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.

[6]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[7]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[8]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[9]  Zanke,et al.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 , 2008, Nature Genetics.

[10]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[11]  C. Chang,et al.  Polymorphisms in TGFβ and TNFα are associated with the myelodysplastic syndrome phenotype , 2007 .

[12]  Wei He,et al.  Hematopoiesis Controlled by Distinct TIF1γ and Smad4 Branches of the TGFβ Pathway , 2006, Cell.

[13]  Y. Mándi,et al.  Genetic polymorphisms in patients with myelodysplastic syndrome. , 2005, Acta microbiologica et immunologica Hungarica.

[14]  T. Takayama,et al.  Involvement of transforming growth factor-β and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis , 2005, Leukemia.

[15]  R. Akhurst.  TGFβ signaling in health and disease , 2004, Nature Genetics.

[16]  G. Mufti,et al.  Apoptosis in the myelodysplastic syndromes. , 2003, Current hematology reports.

[17]  K. Karube,et al.  Imbalance Between Apoptosis and Telomerase Activity in Myelodysplastic Syndromes: Possible Role in Ineffective Hemopoiesis , 2003, Leukemia & lymphoma.

[18]  Ying E. Zhang,et al.  TGF‐β receptor‐activated p38 MAP kinase mediates Smad‐independent TGF‐β responses , 2002 .

[19]  A. Verma,et al.  Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia1 , 2002, The Journal of Immunology.

[20]  G. Saberwal,et al.  Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome , 2002, International journal of hematology.

[21]  A. Verma,et al.  Activation of the p38 Mitogen-activated Protein Kinase Mediates the Suppressive Effects of Type I Interferons and Transforming Growth Factor-β on Normal Hematopoiesis* , 2002, The Journal of Biological Chemistry.

[22]  P. Venugopal,et al.  The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes , 2001, British journal of haematology.

[23]  R. Lloyd,et al.  Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. , 2000, International journal of hematology.

[24]  A. Raza,et al.  Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. , 1999, Anticancer research.

[25]  P. Greenberg,et al.  Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. , 1998, Leukemia research.

[26]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[27]  H. Preisler,et al.  Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. , 1995, Blood.

[28]  M. Sporn,et al.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Zavadil,et al.  Quantitative analysis of miRNA expression in epithelial cells and tissues. , 2012, Methods in molecular biology.

[30]  E. Estey,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use , 2000 .

[31]  P. Greenberg,et al.  Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.

[32]  K. Miyazono,et al.  Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. , 1992, Growth factors.

[33]  P. Greenberg.  Biologic nature of the myelodysplastic syndromes. , 1987, Acta haematologica.